The global market for hydrocodone/acetaminophen, commonly known by the brand name Norco, has seen significant fluctuations in demand due to evolving regulations and changing prescribing trends. In 2021, the global market for prescription opioids was valued at approximately $4.7 billion, with hydrocodone accounting for a substantial share. The increasing awareness regarding opioid addiction has led to more stringent regulations, impacting production and distribution channels. Nevertheless, hydrocodone/acetaminophen remains a widely prescribed pain management option, especially in the United States.

Norco is one of the leading brands of hydrocodone/acetaminophen, primarily marketed in the United States. It holds a significant market share of approximately 25% in the opioid analgesics segment. In 2020, AbbVie’s revenue from Norco was estimated at $1.3 billion, reflecting its continued popularity among healthcare providers.

Vicodin, another product by AbbVie, is a well-known alternative to Norco. It once dominated the market with a share of about 30% but has seen a decline due to increased scrutiny on opioid prescriptions. In 2021, Vicodin’s sales were approximately $800 million, highlighting its ongoing relevance in pain management.

Lortab, produced by Teva Pharmaceuticals, is a combination of hydrocodone and acetaminophen that has maintained a market presence. With a market share of around 10%, Lortab generated sales of roughly $400 million in 2020. Its availability in various dosages has contributed to its sustained demand.

Hycet is another hydrocodone/acetaminophen combination that has gained traction, particularly in the liquid formulation segment. Alvogen reported sales for Hycet at approximately $200 million in 2020, catering to patients with swallowing difficulties and enhancing accessibility.

Maxidone, produced by InvaGen, is a less widely known brand but remains relevant in the market. It holds a market share of around 5% with sales estimated at $150 million in 2020. Its competitive pricing strategy has allowed it to capture a niche segment of the market.

Zydone, manufactured by Zydus Cadila, is another combination product that has seen moderate success. With a market share of approximately 3%, its sales were around $100 million as of 2020. It has gained popularity due to its effective pain relief profile.

Dolgic, produced by Bristol-Myers Squibb, is a combination product that offers significant pain relief. Although its market share is around 2%, it generated sales of approximately $80 million in 2020, primarily due to its unique formulation.

Purdue Pharma offers a variety of pain management products, including a hydrocodone/acetaminophen combination. While specific sales figures are not public, Purdue’s overall presence in the opioid market remains substantial, contributing to its relevance.

Hycodan is another formulation that includes hydrocodone, primarily used for cough relief. Hikma Pharmaceuticals has seen moderate demand for this product, with estimated sales around $60 million in 2020.

Bupap, manufactured by Kremers Urban, rounds out the list of notable hydrocodone/acetaminophen products. With a smaller market share but competitive pricing, its estimated sales were around $50 million in 2020. Its positioning as a budget-friendly alternative has attracted a specific market segment.

The hydrocodone/acetaminophen market is undergoing a transformative phase, with a projected CAGR of 4.5% from 2022 to 2027. Regulatory pressures are leading to a decline in prescription rates for opioids, prompting pharmaceutical companies to reformulate existing products to enhance safety profiles. For instance, the total opioid pain medication market reached approximately $5.3 billion in 2022, indicating a shift towards more controlled and responsible prescribing practices. As the industry adapts, companies focusing on innovation and patient safety will likely remain at the forefront of this evolving market landscape.

Related Analysis: View Previous Industry Report

The post Top 10 Hydrocodone/Acetaminophen (Norco appeared first on ESSFeed.